Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 13/20 | 0.66 |
| ▸ | KIF11 | P52732 | 1/20 | 0.56 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.46 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.46 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.45 |
| ▸ | ACR | P10323 | 1/20 | 0.45 |
| ▸ | CES2 | O00748 | 1/20 | 0.45 |
| ▸ | CES1 | P23141 | 1/20 | 0.45 |
| ▸ | PRTN3 | P24158 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12727386 | 0.89 | KIF11 (0.56) | ELANEKIF11CYP11B1CYP11B2PRSS1 | |
| SCHEMBL22369614 | 0.85 | ELANE (0.86) | ELANEPRTN3 | |
| SCHEMBL16904842 | 0.84 | ELANE (0.70) | ELANE | |
| SCHEMBL17678829 | 0.84 | ELANE (0.70) | ELANEPRTN3 | |
| SCHEMBL18479637 | 0.84 | ELANE (0.59) | ELANE | |
| SCHEMBL18994834 | 0.82 | KIF11 (0.50) | ELANEKIF11CYP11B1CYP11B2PRSS1 | |
| SCHEMBL15495793 | 0.82 | ELANE (0.50) | ELANEKIF11CYP11B1CYP11B2PRSS1 | |
| SCHEMBL11991249 | 0.82 | KIF11 (0.50) | ELANEKIF11CYP11B1CYP11B2PRSS1 | |
| SCHEMBL839809 | 0.80 | KIF11 (0.59) | ELANEKIF11CYP11B1CYP11B2PRSS1 | |
| SCHEMBL13551942 | 0.80 | ELANE (0.70) | ELANEPRTN3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11357970-B2 | Biomedical electrode composition, biomedical electrode and method for manufacturing the biomedical electrode | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2022-06-14 | — | — | US | disclosed |
| US-11008339-B2 | Substituted pyrazole compounds containing pyrimidine and preparation method and use thereof | SHENYANG SINOCHEM AGROCHEMICALS R&D CO., LTD. (CN) | 2021-05-18 | — | — | US | disclosed |
| US-20180193632-A1 | BIOMEDICAL ELECTRODE COMPOSITION, BIOMEDICAL ELECTRODE AND METHOD FOR MANUFACTURING THE BIOMEDICAL ELECTRODE | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2018-07-12 | — | — | US | disclosed |
| US-20180141961-A1 | Substituted Pyrazole Compounds Containing Pyrimidine and Preparation Method and Use Thereof | SHENYANG SINOCHEM AGROCHEMICALS R&D CO., LTD. (CN) | 2018-05-24 | — | — | US | disclosed |
| US-9682962-B2 | Pyrazolyl pyrimidinamine compound and application thereof | SHENYANG SINOCHEM AGROCHEMICALS R&D CO., LTD. (CN) | 2017-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180193632-A1 | BIOMEDICAL ELECTRODE COMPOSITION, BIOMEDICAL ELECTRODE AND METHOD FOR MANUFACTURING THE BIOMEDICAL ELECTRODE | KCNN2, KCNN1, HCN4 | ELANE 647/4885KIF11 1897/4885CYP11B1 3921/4885 |
| US-20180141961-A1 | Substituted Pyrazole Compounds Containing Pyrimidine and Preparation Method and Use Thereof | APRT, GART, PNP | ELANE 3827/4885KIF11 3898/4885CYP11B1 644/4885 |
| US-11008339-B2 | Substituted pyrazole compounds containing pyrimidine and preparation method and use thereof | APRT, GART, PNP | ELANE 3827/4885KIF11 3898/4885CYP11B1 644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.